February 19th 2024
In the open-label, phase 1 study, participants' own T cells will be extracted and engineered to target and eliminate autoreactive B cells and to potentially reset the immune system.
September 11th 2023
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis